FMP
Eloxx Pharmaceuticals, Inc.
ELOX
OTC
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
0.0001 USD
0 (0%)
Historical Prices
From:
To:
About
ceo
Mr. Sumit Aggarwal M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://www.eloxxpharma.comexchange
OTC
Description
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founde...
CIK
0001035354
ISIN
US29014R2022
CUSIP
29014R103
Address
480 Arsenal Way
Phone
781 577 5300
Country
US
Employee
18
IPO Date
Apr 26, 1999
Financial Statement
Earnings
ELOX Financial Summary
CIK
0001035354
Exchange
OTC
Industry
Biotechnology
Sector
Healthcare
CUSIP
29014R103
ISIN
US29014R2022
Country
US
Price
0
Beta
-24.6
Volume Avg.
220
Market Cap
314
Shares
-
52-Week
0.0001-1.15
DCF
2.69
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-
P/B
-
Website
https://www.eloxxpharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ELOX News
InvestorPlace
Dec 5, 2023
Off the Beaten Path: 3 Delisted Stocks for The Speculative I...
While getting kicked off an exchange typically signals about the biggest warning sign you can possibly receive, a (somewhat) rational argument exists for delisted stocks to buy. Psychologically, companies go through much anxiety doing whatever they can to stay listed in a major exchange.
MarketBeat
Jul 12, 2023
This Small Cap Stock Surged Over 100%
Arguably the most impressive mover yesterday was a stock you have probably never heard of. Shares of Eloxx Pharmaceuticals NASDAQ: ELOX rocketed almost 100% yesterday after receiving an increased price target from Oppenheimer.
PennyStocks
Jul 11, 2023
Penny Stocks to Watch: Why Is ELOX Stock Skyrocketing?
Most traders dream of hitting it big, and penny stocks are some of the most attractive for day traders. It can be any given session where we see at least a handful of cheap stocks under $5 explode.
InvestorPlace
May 16, 2023
Why Is Eloxx Pharmaceuticals (ELOX) Stock Down 27% Today?
Eloxx Pharmaceuticals (NASDAQ: ELOX ) stock is falling hard on Tuesday after the company provided a weak earnings report for Q1 2023. The bad news for ELOX stock starts with its losses per share of $2.88 cents.
Zacks Investment Research
May 15, 2023
Senesco Technologies Inc. (ELOX) Reports Q1 Loss, Lags Reven...
Senesco Technologies Inc. (ELOX) came out with a quarterly loss of $2.88 per share versus the Zacks Consensus Estimate of a loss of $2.55. This compares to loss of $5.20 per share a year ago.
GlobeNewsWire
Mar 6, 2023
Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Ann...
WATERTOWN, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it will present at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13th at 12:00 PM ET.
PennyStocks
Jan 5, 2023
5 Hot Penny Stocks Exploding After News This Week
Hot penny stocks with news to watch this week. The post 5 Hot Penny Stocks Exploding After News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Zacks Investment Research
Sep 16, 2022
Eloxx (ELOX) Down After Cystic Fibrosis Study Fails to Meet ...
Eloxx Pharmaceuticals' (ELOX) phase II combination study evaluating pipeline candidate ELX-02 in cystic fibrosis fails to achieve statistical significance in efficacy endpoints.
